Anti-interferon alpha antibodies and autoantibodies in patients with Beh double dagger et's disease uveitis treated with recombinant human interferon alpha-2a

---

Atıf İçin Kopyala

Aydinoglu-Candan O., Araz-Ersan B., Gül A., Badur S., Tugal-Tutkun I.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, cilt.253, sa.3, ss.457-465, 2015 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 253 Sayı: 3
• Basım Tarihi: 2015
• Doi Numarası: 10.1007/s00417-014-2856-3
• Dergi Adı: GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Sayfa Sayıları: ss.457-465
• Anahtar Kelimeler: Behcet's disease, Interferon, Anti-interferon alpha antibody, Binding antibody, Autoantibody, CHRONIC HEPATITIS-C, LONG-TERM EFFICACY, BEHCETS-DISEASE, MULTIPLE-SCLEROSIS, AUTOIMMUNE-DISEASE, NEUTRALIZING ANTIBODIES, BETA ANTIBODIES, THERAPY, SAFETY, PANUVEITIS
• İstanbul Üniversitesi Adresli: Evet

Özet

Recombinant human (rh) interferon alpha2a (IFN-alpha 2a) therapy is successfully used for the treatment of Beh double dagger et's disease (BD) uveitis refractory to conventional immunosuppressive treatment.